Hayardeny; Liat

Patent Applications and Registrations

Patent applications and USPTO patent grants for Hayardeny; Liat.The latest application filed is for "treatment of progressive forms of multiple sclerosis with laquinimod".

Company Profile

0.4.32

Hayardeny; Liat - Tel-Aviv IL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Treatment Of Progressive Forms Of Multiple Sclerosis With Laquinimod App 20180064702 - Tarcic; Nora ; et al.	2018-03-08
Genetic Markers Predictive Of Response To Glatiramer Acetate App 20180002753 - TCHELET; Amir ; et al.	2018-01-04
Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And Fingolimod App 20170354651 - Hayden; Michael ; et al.	2017-12-14
Treatment Of Bdnf-related Disorders Using Laquinimod App 20170239234 - Hayardeny; Liat	2017-08-24
Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And Fingolimod App 20170224674 - Hayden; Michael ; et al.	2017-08-10
Genetic markers predictive of response to glatiramer acetate Grant 9,702,007 - Tchelet , et al. July 11, 2	2017-07-11
Treatment of BDNF-related disorders using laquinimod Grant 9,585,878 - Hayardeny March 7, 2	2017-03-07
Biological Characterization Of A Glatiramer Acetate Related Drug Product Using Mammalian And Human Cells App 20170003277 - Hayden; Michael ; et al.	2017-01-05
Treatment of BDNF-Related Disorders Using Laquinimod App 20160243103 - Hayardeny; Liat	2016-08-25
Gene Expression Biomarkers Of Laquinimod Responsiveness App 20160201132 - Hayardeny; Liat ; et al.	2016-07-14
Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And Fingolimod App 20160074380 - Hayden; Michael ; et al.	2016-03-17
Genetic Markers Predictive Of Response To Glatiramer Acetate App 20150110733 - TCHELET; Amir ; et al.	2015-04-23
Combination Therapy With Glatiramer Acetate And Rasagiline For The Treatment Of Multiple Sclerosis App 20140271532 - Kreitman; Rivka ; et al.	2014-09-18
Treatment Of Progressive Forms Of Multiple Sclerosis With Laquinimod App 20140235670 - Tarcic; Nora ; et al.	2014-08-21
Combination Therapy With Glatiramer Acetate And Rasagiline For The Treatment Of Multiple Sclerosis App 20120027718 - Kreitman; Rivka ; et al.	2012-02-02
Treatment of BDNF-related disorders using laquinimod App 20110034508 - Hayardeny; Liat	2011-02-10
Markers associated with the therapeutic efficacy of glatiramer acetate App 20100285600 - Lancet; Doron ; et al.	2010-11-11
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis App 20100167983 - Kreitman; Rivka ; et al.	2010-07-01
Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis App 20080261894 - Kreitman; Rivka ; et al.	2008-10-23
Combination Therapy With Glatiramer Acetate and Riluzole App 20070244056 - Hayardeny; Liat ; et al.	2007-10-18
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis App 20070037740 - Pinchasi; Irit ; et al.	2007-02-15
Markers associated with the therapeutic efficacy of glatiramer acetate App 20060240463 - Lancet; Doron ; et al.	2006-10-26
Propargyl-trifluoromethoxy-amino-benzothiazole derivatives App 20040176430 - Sterling, Jeffrey ; et al.	2004-09-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.